Genmab A/S has raised DKK 998 million (€134 million) following the pricing of a previously-announced private share placement to support development of its therapeutic antibody portfolio. The company announced the results on 24 January. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
